Multimeric T-Cell Modulatory Polypeptides for Selective Immune Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapies face challenges in selectively modulating T-cell responses, as existing immunomodulatory polypeptides often exhibit high affinity to non-cognate co-immunomodulatory polypeptides, leading to non-specific immune activation and potential autoimmunity risks.
Innovation Solution
Development of T-cell modulatory multimeric polypeptides (TMMPs) that comprise an immunomodulatory polypeptide with reduced binding affinity to cognate co-immunomodulatory polypeptides, specifically designed to bind to T-cell receptors with enhanced selectivity, utilizing epitope-specific and immunomodulatory domains to modulate T-cell activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing immunomodulatory polypeptides are used to activate T cells, then immune response activation is achieved, but non-specific binding to non-cognate co-immunomodulatory polypeptides occurs leading to autoimmunity risks
Solution Approach 1:
The patent applies local quality by engineering the immunomodulatory polypeptide with non-uniform binding characteristics: high affinity for cognate co-immunomodulatory polypeptides (specific T-cell targets) and low affinity for non-cognate polypeptides. This differential binding affinity creates localized specificity at the molecular interaction level, ensuring that activation occurs only at the intended target site while avoiding off-target effects.
Solution Approach 2:
The patent employs parameter changes by modifying the binding affinity parameter of the immunomodulatory polypeptide. Specifically, the polypeptide is engineered to exhibit a threshold-based binding characteristic where it only binds effectively when the affinity exceeds a certain threshold (cognate binding), while sub-threshold binding to non-cognate polypeptides is minimized. This parameter optimization resolves the contradiction between sufficient activation and specific targeting.
2Power
If high affinity binding to co-immunomodulatory polypeptides is achieved, then strong T-cell activation occurs, but selectivity for specific epitopes is reduced
Solution Approach 1:
The patent applies dynamics by creating a conditional binding system where the immunomodulatory polypeptide's activation strength is dynamically regulated by the presence of specific epitope-MHC complexes. The polypeptide exhibits high power (strong activation) only when bound to the correct cognate target displaying the specific epitope, while maintaining low power when encountering non-cognate targets. This dynamic response resolves the contradiction between activation strength and selectivity.
3Productivity
If broad immunomodulatory activity is provided, then general immune response is enhanced, but epitope-specific responses are diluted
Solution Approach 1:
The patent applies segmentation by dividing the immune response into epitope-specific segments. The immunomodulatory polypeptide is designed to segment the broad immune response into discrete, epitope-specific activation events. Each polypeptide instance targets a specific epitope-MHC combination, creating modular, segmentable immune activation that maintains overall productivity while preserving precision for each epitope target.
Data Source
AI summary
The present disclosure provides T-cell modulatory multimeric polypeptides that comprise an immunomodulatory polypeptide and that comprise an epitope-presenting a human papillomavirus (HPV) peptide. A T-cell modulatory multimeric polypeptide is useful for modulating the activity of a T cell, and for modulating an immune response in an individual.